MRI-based Nomogram Predicts the Risk of Progression of Unresectable Hepatocellular Carcinoma After Combined Lenvatinib and anti-PD-1 Antibody Therapy
Ruofan Sheng, Mengsu Zeng, Kaipu Jin, Yunfei Zhang, Dong Wu, Hui‐Chuan Sun
Topics & Concepts
MedicineLenvatinibNomogramHazard ratioInternal medicineOncologyHepatocellular carcinomaMagnetic resonance imagingProportional hazards modelConfidence intervalRadiologySorafenibHepatocellular Carcinoma Treatment and PrognosisRadiomics and Machine Learning in Medical ImagingMRI in cancer diagnosis